Madrigal Pharmaceuticals Inc Receives a Rating Update from a Top Analyst

By Jason Carr

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) today. The company’s shares opened today at $124.41.

According to, Baral is a top 25 analyst with an average return of 33.7% and a 55.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Intra-Cellular Therapies.

Madrigal Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $174.

Based on Madrigal Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $8.45 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases.